Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITPR3 | Q14573 | 1/20 | 0.44 |
| ▸ | ITPR1 | Q14643 | 1/20 | 0.44 |
| ▸ | LPAR3 | Q9UBY5 | 7/20 | 0.41 |
| ▸ | LPAR2 | Q9HBW0 | 6/20 | 0.41 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.41 |
| ▸ | FDPS | P14324 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | BLM | P54132 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.38 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | THPO | P40225 | 1/20 | 0.35 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.35 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.35 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23631720 | 0.89 | ITPR3 (0.47) | ITPR3ITPR1LPAR3LPAR2LPAR1 | |
| SCHEMBL23631717 | 0.87 | ITPR3 (0.49) | ITPR3ITPR1LPAR3LPAR2LPAR1 | |
| SCHEMBL19124751 | 0.82 | — | — | |
| SCHEMBL14727907 | 0.82 | LPAR3 (0.53) | ITPR3ITPR1LPAR3LPAR2LPAR1 | |
| SCHEMBL2755680 | 0.82 | LPAR3 (0.44) | ITPR3ITPR1LPAR3LPAR2LPAR1 | |
| SCHEMBL10025915 | 0.82 | ITPR3 (0.42) | ITPR3ITPR1LPAR3LPAR2LPAR1 | |
| SCHEMBL18121613 | 0.82 | ITPR3 (0.42) | ITPR3ITPR1LPAR3LPAR2LPAR1 | |
| SCHEMBL8829466 | 0.82 | BTN3A1 (0.47) | ITPR3ITPR1LPAR3LPAR2LPAR1 | |
| SCHEMBL19237471 | 0.82 | LPAR3 (0.44) | ITPR3ITPR1LPAR3LPAR2LPAR1 | |
| SCHEMBL26079101 | 0.82 | LPAR3 (0.44) | ITPR3ITPR1LPAR3LPAR2LPAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220056451-A1 | HBV BINDING OLIGONUCLEOTIDES AND METHODS OF USE | ALIGOS THERAPEUTICS, INC. | 2022-02-24 | — | — | US | disclosed |
| US-20180078612-A1 | INTRACELLULAR DELIVERY SYSTEM AND METHODS | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2018-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220056451-A1 | HBV BINDING OLIGONUCLEOTIDES AND METHODS OF USE | HAVCR2, POLRMT, DCLRE1B | ITPR3 4082/4885ITPR1 3884/4885LPAR3 2401/4885 |
| US-20180078612-A1 | INTRACELLULAR DELIVERY SYSTEM AND METHODS | LNPEP, CHERP, CHMP4B | ITPR3 2657/4885ITPR1 2284/4885LPAR3 1412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.